Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Lobeglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | MPC2 | O95563 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeglitazone SCHEMBL20125583 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL2742697 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL20125580 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL29356140 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884045 | 0.90 | PPARG (0.86) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL19454945 | 0.89 | PPARG (0.85) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883617 | 0.83 | PPARG (0.75) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884168 | 0.82 | PPARG (0.74) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883649 | 0.81 | PPARG (0.73) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883494 | 0.79 | PPARG (0.69) | PPARGPPARARXRARARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024162731-A1 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING LOBEGLITAZONE AND SITAGLIPTIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-08-08 | — | — | WO | claimed |
| WO-2024063568-A1 | COMPOSITION AND COMBINATION THERAPY FOR TREATMENT OF TYPE 2 DIABETES MELLITUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-03-28 | — | — | WO | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4605080-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | ACLIPSE TWO INC. | 2025-08-21 | — | — | US | disclosed |
| WO-2025049710-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE DISEASE TREATMENTS | ACLIPSE TWO INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4511030-A2 | TREATMENT OF GASTROINTESTINAL DISEASES | Aclipse Two Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240366596-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024162731-A1 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING LOBEGLITAZONE AND SITAGLIPTIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-08-08 | — | — | WO | disclosed |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2023205683-A2 | TREATMENT OF GASTROINTESTINAL DISEASES | ACLIPSE TWO INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230181673-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230130739-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2023009710-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022225902-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022225903-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4051281-A1 | TREATMENT OF DIABETIC NEPHROPATHY WITH AN SGC STIMULATOR | Cyclerion Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | PPARG 784/4885PPARA 2599/4885RXRA 3509/4885 |
| US-20240366596-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | GUCY1A2, GUCY1A1, GUCY1B2 | PPARG 548/4885PPARA 2080/4885RXRA 4487/4885 |
| US-20230130739-A1 | DEUTERATED sGC STIMULATORS | PDE2A, GUCY1A2, PDE3A | PPARG 869/4885PPARA 2846/4885RXRA 3209/4885 |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | FABP6, SLC10A2, FABP2 | PPARG 17/4885PPARA 40/4885RXRA 275/4885 |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | PPARG 843/4885PPARA 2871/4885RXRA 3677/4885 |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1A1, GUCY1B2 | PPARG 1306/4885PPARA 3620/4885RXRA 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.